Yael Capital
雅亿资本
Yael Capital (雅亿资本) is a Chinese venture capital fund that appears in elsewhere's corpus primarily as a co-investor alongside larger institutions, with activity concentrated in 2020–2021 . It participated in the Series B+ round of Shenzhen-based microbiome drug developer Unknown Biotech (未知君) in November 2020, alongside Spring Capital, Gaorong Capital, and 5Y Capital . In 2021, it followed on in two deals led by 5Y Capital: the angel+ round of cancer targeted-drug developer Signet Therapeutics (希格生科) in October , and the angel round of bio-based materials startup GS Biotech (中科国生) in November . The fund's positioning and independent strategy are not directly described in the retrieved material — elsewhere's corpus captures it mainly through its presence in syndicates led by others.
AI-generated — may contain errors, please verify.
Coverage
If wisdom lacks the courage of execution, it is all in vain | 5Y News Monthly
The big news from last month.
五源资本·Summer rains bring gentle relief, good things flourish like green grass | Z News
Long, languid July.
真格基金·5Y News | 5Y Capital Portfolio Company ReviR Therapeutics Raises $30 Million in Series A Funding
Continuing to advance "oral gene therapy" through AI+RNA.
五源资本·二月，回归对世界的想象力 | 5Y News Monthly
上个月发生的大事儿。
五源资本·5Y News | Portfolio Company PAM2L Biotechnologies Closes Pre-A Round of Over 100 Million RMB
Leveraging synthetic biology and machine learning as dual engines to drive bio-based materials and product development.
五源资本·December, Everything Within Reach | 5Y News Monthly
The big news from last month.
五源资本·5Y News | "中科国生" Raises Tens of Millions of RMB in Angel Round to Develop and Promote Functional Bio-based New Materials
Transforming lives with biomass.
五源资本·November: Foresight and Boundless Imagination | 5Y News Monthly
The big news from last month.
五源资本·5Y News | Signet Therapeutics Raises Nearly $10 Million to Power AI-Enabled Innovative Targeted Drug Development Through Disease Modeling Platform
Advancing pharmaceutical innovation in China.
五源资本·5Y News｜Unknown Closes Tens of Millions of Dollars in Series B+ Funding to Advance Microbiome Drug Clinical Trials
Leading domestic microbiome therapeutics company Unknown has recently completed a tens-of-millions-of-dollars Series B+ funding round, with continued backing from 5Y Capital.
五源资本·
